How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
35
RHHVF Quote, Financials, Valuation and Earnings
Last price:
$457.00
Seasonality move
:
0.69%
Day range:
$457.00 - $471.58
52-week range:
$277.00 - $478.81
Dividend yield:
2.4%
P/E ratio:
23.86x
P/S ratio:
4.97x
P/B ratio:
6.80x
Volume:
21.1K
Avg. volume:
13K
1-year change:
44.92%
Market cap:
$364.8B
Revenue:
$74.1B
EPS (TTM):
$19.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
$19.8B | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$1.5M | -$0.22 | 11.32% | -18.31% | $9.21 |
|
CRSP
CRISPR Therapeutics AG
|
$3.9M | -$1.23 | 197.87% | -30.07% | $84.39 |
|
GALDY
Galderma Group AG
|
-- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.32 | 25.24% | 4402.9% | $404.57 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
$458.53 | -- | $364.8B | 23.86x | $11.00 | 2.4% | 4.97x |
|
ACIU
AC Immune SA
|
$2.96 | $9.21 | $297.8M | -- | $0.00 | 0% | 57.72x |
|
CRSP
CRISPR Therapeutics AG
|
$45.88 | $84.39 | $4.4B | -- | $0.00 | 0% | 104.65x |
|
GALDY
Galderma Group AG
|
$38.05 | -- | $44.7B | 130.29x | $0.03 | 0.04% | 9.65x |
|
ONC
BeOne Medicines Ltd.
|
$352.00 | $404.57 | $39B | 677.18x | $0.00 | 0% | 7.86x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
53.53% | -0.533 | -- | 0.88x |
|
ACIU
AC Immune SA
|
6.95% | 3.733 | 2.01% | 1.10x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 2.738 | 3.47% | 16.13x |
|
GALDY
Galderma Group AG
|
26.02% | 1.432 | -- | 0.80x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | -0.304 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
-- | -- | 14.32% | 28.65% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
GALDY
Galderma Group AG
|
-- | -- | 3.62% | 4.9% | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Roche Holding AG vs. Competitors
-
Which has Higher Returns RHHVF or ACIU?
AC Immune SA has a net margin of -- compared to Roche Holding AG's net margin of -1688.87%. Roche Holding AG's return on equity of 28.65% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About RHHVF or ACIU?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.21 which suggests that it could grow by 211.38%. Given that AC Immune SA has higher upside potential than Roche Holding AG, analysts believe AC Immune SA is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 ACIUAC Immune SA4 0 0 -
Is RHHVF or ACIU More Risky?
Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.392% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.038%.
-
Which is a Better Dividend Stock RHHVF or ACIU?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.4%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or ACIU?
Roche Holding AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Roche Holding AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Roche Holding AG's price-to-earnings ratio is 23.86x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.97x versus 57.72x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG4.97x 23.86x -- -- ACIUAC Immune SA57.72x -- $1.2M -$19.8M
-
Which has Higher Returns RHHVF or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Roche Holding AG's net margin of -11973.12%. Roche Holding AG's return on equity of 28.65% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About RHHVF or CRSP?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $84.39 which suggests that it could grow by 83.94%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 CRSPCRISPR Therapeutics AG12 9 1 -
Is RHHVF or CRSP More Risky?
Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.392% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.724, suggesting its more volatile than the S&P 500 by 72.403%.
-
Which is a Better Dividend Stock RHHVF or CRSP?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.4%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or CRSP?
Roche Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Roche Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Roche Holding AG's price-to-earnings ratio is 23.86x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.97x versus 104.65x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG4.97x 23.86x -- -- CRSPCRISPR Therapeutics AG104.65x -- $889K -$106.4M
-
Which has Higher Returns RHHVF or GALDY?
Galderma Group AG has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 28.65% beat Galderma Group AG's return on equity of 4.9%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B GALDYGalderma Group AG-- -- $10.4B -
What do Analysts Say About RHHVF or GALDY?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Galderma Group AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Roche Holding AG has higher upside potential than Galderma Group AG, analysts believe Roche Holding AG is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 GALDYGalderma Group AG0 0 0 -
Is RHHVF or GALDY More Risky?
Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.392% less volatile than S&P 500. In comparison Galderma Group AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RHHVF or GALDY?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.4%. Galderma Group AG offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. Galderma Group AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or GALDY?
Roche Holding AG quarterly revenues are --, which are smaller than Galderma Group AG quarterly revenues of --. Roche Holding AG's net income of -- is lower than Galderma Group AG's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 23.86x while Galderma Group AG's PE ratio is 130.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.97x versus 9.65x for Galderma Group AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG4.97x 23.86x -- -- GALDYGalderma Group AG9.65x 130.29x -- --
-
Which has Higher Returns RHHVF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Roche Holding AG's net margin of 8.84%. Roche Holding AG's return on equity of 28.65% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About RHHVF or ONC?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $404.57 which suggests that it could grow by 14.93%. Given that BeOne Medicines Ltd. has higher upside potential than Roche Holding AG, analysts believe BeOne Medicines Ltd. is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 ONCBeOne Medicines Ltd.19 0 1 -
Is RHHVF or ONC More Risky?
Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.392% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.518, suggesting its less volatile than the S&P 500 by 48.23%.
-
Which is a Better Dividend Stock RHHVF or ONC?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.4%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or ONC?
Roche Holding AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Roche Holding AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Roche Holding AG's price-to-earnings ratio is 23.86x while BeOne Medicines Ltd.'s PE ratio is 677.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.97x versus 7.86x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG4.97x 23.86x -- -- ONCBeOne Medicines Ltd.7.86x 677.18x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
59
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
58
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Sell
26
KELYB alert for Feb 6
Kelly Services, Inc. [KELYB] is up 243.2% over the past day.
Buy
61
SLAB alert for Feb 5
Silicon Laboratories, Inc. [SLAB] is up 0.91% over the past day.
Sell
25
MRCY alert for Feb 6
Mercury Systems, Inc. [MRCY] is up 2.61% over the past day.
